Cordis
A Cardinal Health company

10125412.13
Instructions for Use
Cordis S.M.A.R.T.® CONTROL® Nitinol Stent System
1. Flushing valve
2. Inner shaft: polymeric tube
3. Inner shaft: metallic tube
4. Inner shaft: metallic coil
5. Catheter tip (distal wire lumen)
6. Luer hub (proximal wire lumen)
7. Outer sheath
8. Luer hub (outer sheath)
9. S.M.A.R.T. Stent
10. Inner shaft stent stop
11. Distal radiopaque marker
12. Distal stent markers
13. Proximal stent markers
14. Locking pin
15. Handle
16. Tuning dial
17. Deployment lever
Figure 2. Stent Deployment Using Tuning Dial

Figure 3. Stent Deployment Using Deployment Lever

Figure 4. Stent Deployment Using Two Hands ("Pin and Pull")
### Explanation of symbols on labels and packaging:

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Use-by date" /></td>
<td>Use-by date</td>
</tr>
<tr>
<td><img src="image" alt="Lot number" /></td>
<td>Lot number</td>
</tr>
<tr>
<td><img src="image" alt="Catalogue number" /></td>
<td>Catalogue number</td>
</tr>
<tr>
<td><img src="image" alt="Do not resterilize" /></td>
<td>Do not resterilize</td>
</tr>
<tr>
<td><img src="image" alt="Do not re-use" /></td>
<td>Do not re-use</td>
</tr>
<tr>
<td><img src="image" alt="Non-pyrogenic" /></td>
<td>Non-pyrogenic</td>
</tr>
<tr>
<td><img src="image" alt="n units per box" /></td>
<td>n units per box</td>
</tr>
<tr>
<td><img src="image" alt="Do not use if package is damaged" /></td>
<td>Do not use if package is damaged</td>
</tr>
<tr>
<td><img src="image" alt="Caution" /></td>
<td>Caution</td>
</tr>
<tr>
<td><img src="image" alt="Keep away from sunlight" /></td>
<td>Keep away from sunlight</td>
</tr>
<tr>
<td><img src="image" alt="Keep dry" /></td>
<td>Keep dry</td>
</tr>
<tr>
<td><img src="image" alt="Consult instructions for use" /></td>
<td>Consult instructions for use</td>
</tr>
<tr>
<td><img src="image" alt="Sterilized using ethylene oxide" /></td>
<td>Sterilized using ethylene oxide</td>
</tr>
<tr>
<td><img src="image" alt="Caution: Federal (USA) law restricts this device to sale by or on order of a physician." /></td>
<td>Caution: Federal (USA) law restricts this device to sale by or on order of a physician.</td>
</tr>
<tr>
<td><img src="image" alt="MR Conditional" /></td>
<td>MR Conditional</td>
</tr>
<tr>
<td><img src="image" alt="Recommended Sheath Size" /></td>
<td>Recommended Sheath Size</td>
</tr>
<tr>
<td><img src="image" alt="Manufacturer" /></td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>
I. Device Name
The device brand name is the Cordis S.M.A.R.T.® CONTROL® Nitinol Stent System.

II. Description
The Cordis S.M.A.R.T. CONTROL Nitinol Stent System is designed to deliver a self-expanding stent to the peripheral vasculature via a sheathed delivery system. The outer diameter of the delivery system is specified in the following Stent Delivery System (SDS) Table.

<table>
<thead>
<tr>
<th>Unconstrained Stent Diameter</th>
<th>SDS Outer Diameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-10 mm</td>
<td>6F (2.0 mm)</td>
</tr>
<tr>
<td>12-14 mm</td>
<td>7F (2.3 mm)</td>
</tr>
</tbody>
</table>

Refer to product labeling for stent diameter and SDS outer diameter.

The self-expanding stent is composed of a nickel titanium alloy (nitinol). A total of 12 (6 at each end) tantalum radiopaque markers are located on the ends of the stent. The stent is a flexible, fine mesh tubular prosthesis, that expands upon deployment to appose the vessel wall. Upon deployment, the stent imparts an outward radial force on the luminal surface of the vessel to establish patency.

The delivery system, as shown in Figure 1, is comprised of an inner shaft and an outer sheath that are locked together with a flushing valve (1). The inner shaft is comprised of a polymeric tube (2) covered proximally by a stainless steel hypotube (3) and, distally by a stainless steel coil (4). The inner shaft terminates distally in a catheter tip (5) and originates proximally in a Luer hub (6) designed to accept a .035" (0.89 mm) guidewire.

The outer sheath (7) connects proximally to the flushing valve (1) via a second Luer hub (8). The self-expanding stent (9) is constrained within the space between the polymeric tube (2) and the outer sheath (7). This space is flushed prior to the interventional procedure by injecting fluid via the flushing valve (1). Stent movement during sheath retraction is restricted by an inner shaft stent stop (10) connected to the inner shaft. The outer sheath has a radiopaque marker band (11) at its distal end.

Stent positioning about the target lesion is achieved prior to deployment utilizing the distal stent markers (12) and the proximal stent markers (13). For stent deployment, the locking pin (14) must be removed. Sheath retraction is achieved by grasping the handle (15) in a fixed position with the tuning dial (16) held between the thumb and index finger. Deployment is initiated by rotating the tuning dial (16) with the thumb and index finger [Figure 2] in a clockwise direction until the distal stent markers (12) and the distal end of the stent, visibly appose the vessel wall. With the distal stent markers (12) and the distal end of the stent apposing the vessel wall, stent deployment continues by pulling back on the deployment lever (17) [Figure 3]. Complete deployment of the stent is achieved when the proximal end of the stent and the proximal stent markers (13), visibly appose the vessel wall and the outer sheath radiopaque marker (11) is proximal to the inner shaft stent stop (10).

III. Indications for Use
The Cordis S.M.A.R.T. CONTROL Nitinol Stent System is indicated for use in patients with atherosclerotic disease of peripheral arteries, including iliac and superficial femoral, for TIPSS™ procedures and for palliation of malignant neoplasms in the biliary tree.

IV. Contraindications
Generally, contraindications to PTA are also contraindications for stent placement. Contraindications include, but may not be limited to:

- Patients with highly calcified lesions resistant to PTA.
- Patients with a target lesion with a large amount of adjacent acute or subacute thrombus.
- Stenting of a perforated biliary duct where leakage from the duct could be exacerbated by the stent.
- Patients with uncorrected bleeding disorders.
- Stenting of the bile duct in the presence of severe ascites.
- Stenting of intra-cranial arteries.

* TIPSS is Transjugular Intrahepatic Portosystemic Shunt
V. Warnings

- Persons with allergic reactions to nickel titanium (nitinol) may suffer an allergic response to this implant.
- Placing multiple overlapping stents in the SFA may increase the possibility of stent fracture.
- The black dotted pattern on the grey temperature exposure indicator, found on the pouch, must be clearly visible. Do not use if entire temperature exposure indicator is completely black as the unconstrained stent diameter may have been compromised.
- The Cordis S.M.A.R.T. CONTROL Nitinol Stent System is intended for single use only. DO NOT resterilize and/or reuse the device.
- This product is designed and intended for single use. It is not designed to undergo reprocessing and resterilization after initial use.
- Reuse of this product, including after reprocessing and/or re-sterilization, may cause a loss of structural integrity which could lead to a failure of the device to perform as intended and may lead to a loss of critical labeling/use information all of which present a potential risk to patient safety.
- Do not use if the pouch is opened or damaged.
- Use the stent system prior to the “Use By” date specified on the package.
- Do not use with Ethiodol or Lipiodol† contrast media.
- Do not expose the delivery system to organic solvents (e.g. alcohol).
- The stent is not designed for repositioning or recapturing.
- Once the stent is partially deployed, it cannot be recaptured using the stent delivery system.
- Avoid stent placement that may obstruct access to a vital side branch.
- As with any type of vascular implant, infection, secondary to contamination of the stent, may lead to thrombosis, pseudoaneurysm or rupture into a neighboring organ or the retroperitoneum.
- The stent may cause a thrombus, distal embolization or may migrate from the site of the implant down the arterial lumen.
- Overstretching of the artery may result in rupture and lifethreatening bleeding.
- Stenting across a major bile duct branch could lead to compromised future diagnostic or therapeutic procedures.
- Insufficient clinical data exists to support use of the Cordis S.M.A.R.T. CONTROL Nitinol Stent System in renal arteries.

It is not recommended that the stent be used in patients with the following characteristics:
- Patients with poor renal function, who, in the physicians opinion, may be at risk for a reaction to contrast medium.
- Pregnant patients.
- Patients with bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy.
- Patients with perforated vessels evidenced by extravasation of contrast media.
- Patients who have aneurysmal dilation immediately proximal or distal to the lesion.

VI. Precautions

- The device is intended for use by physicians who have received appropriate training in such interventional techniques as percutaneous transluminal angioplasty and placement of intravascular stents.
- The delivery system is not designed for use with power injection systems.
- When catheters are in the body, they should be manipulated only under fluoroscopy.
- Radiographic equipment that provides high quality images is needed.
- When treating multiple lesions, the most distal lesion should be stented first followed by the stenting of proximal lesions. Stenting in this order eliminates the need to cross and reduces the chance of dislodging stents which have already been placed.
- Recrossing a partially or fully deployed stent with adjunct devices must be performed with caution.
- In the event of thrombosis of the expanded stent, thrombolysis and PTA should be attempted.
- In the event of complications such as infection, pseudoaneurysm or fistulization, surgical removal of the stent may be required. Standard surgical procedure is appropriate.
- In patients requiring the use of antacids and/or H2- antagonists before or immediately following stent placement, oral absorption of antiplatelet agents (e.g. aspirin) may be adversely affected.
- Prior to stent deployment remove all slack from the catheter delivery system (see “Stent Deployment Procedure”).
- Store in a cool, dark, dry place.

VII. Potential Complications

Procedures requiring percutaneous catheter introduction should not be attempted by physicians unfamiliar with the possible complications. Complications may occur at any time during or after the procedure. Potential complications may include, but are not limited to:
- Amputation
- Aneurysm and pseudoaneurysm formation
- Arrhythmia

† Ethiodol and Lipiodol are trademarks of Guerbet S.A.
- Arteriovenous fistula
- Bile duct perforation
- Blue toe syndrome
- Coronary ischemia
- Death
- Disseminated intravascular coagulation
- Drug reactions, allergic reaction to contrast medium or to the implanted device
- Embolism
- Emergency artery bypass graft surgery
- G.I. bleeding from anticoagulation/antiplatelet medication
- Hematoma
- Hemobilia
- Hemorrhage
- Hemorrhagic or embolic stroke/ TIA
- Iliac artery spasm
- Intimal tear/dissection
- Liver abscess
- New or worse encephalopathy
- Pancreatitis
- Parenchymal hemorrhage
- Pneumothorax
- Renal failure
- Respiratory arrest
- Sepsis/infection
- Sludge occlusion
- Stent migration/embolization
- Stent misplacement
- Stent obstruction secondary to tumor growth
- Subcapsular liver hematoma
- Thrombosis
- Tissue necrosis
- Tumor overgrowth at the stent ends
- Vascular injury, including perforation, rupture and dissection
- Vessel occlusion, restenosis or recurrent stricture

VIII. Directions for Use

Pre-Procedural

The patient may be started on nonbuffered, nonenteric-coated aspirin one or two days prior to the procedure per standard hospital dosing guidelines or as prescribed by a physician.

The percutaneous placement of the stent in a stenotic or obstructed artery should be done in an angiography procedure room. Angiography should be performed to map the extent of the lesion(s) and the collateral flow. If thrombus is present or suspected, thrombolysis should precede stent deployment using standard accepted practice. (Access vessels must be sufficiently patent, or sufficiently recanalized, to proceed with further intervention.) Patient preparation and sterile precautions should be the same as for any angioplasty procedure.

Procedure

1. **Inject Contrast Media**
   Perform a percutaneous angiogram using standard technique. For biliary procedures the biliary tree may be injected.

2. **Evaluate and Mark Lesion or Stricture**
   Fluoroscopically evaluate and mark the lesion or stricture, observing the most distal level of the stenosis or stricture.

3. **Select Stent Size**
   Measure the length of the target lesion to determine the length of stent(s) required.

   Measure the diameter of the reference vessel (proximal and distal to the lesion). It is necessary to select a stent that has an unconstrained diameter at least 1 mm larger than the largest reference vessel diameter to achieve secure placement according to the following Stent Size Selection Table.
Stent Size Selection Table

<table>
<thead>
<tr>
<th>Vessel Lumen Diameter</th>
<th>Unconstrained Stent Diameter</th>
<th>Length Foreshortening</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0 - 5.0 mm</td>
<td>6.0 mm</td>
<td>1.1%</td>
</tr>
<tr>
<td>5.0 - 6.0 mm</td>
<td>7.0 mm</td>
<td>1.8%</td>
</tr>
<tr>
<td>6.0 - 7.0 mm</td>
<td>8.0 mm</td>
<td>2.8%</td>
</tr>
<tr>
<td>7.0 - 8.0 mm</td>
<td>9.0 mm</td>
<td>4.0%</td>
</tr>
<tr>
<td>8.0 - 9.0 mm</td>
<td>10.0 mm</td>
<td>5.5%</td>
</tr>
<tr>
<td>9.0 - 11.0 mm</td>
<td>12.0 mm</td>
<td>4.7%</td>
</tr>
<tr>
<td>11.0 - 13.0 mm</td>
<td>14.0 mm</td>
<td>5.4%</td>
</tr>
</tbody>
</table>

Refer to product labeling for stent diameter and length.

**Note:** The percent foreshortening of stent length is based upon a mathematical calculation.

4. **Preparation of Stent Delivery System**
   a. Open the box to reveal the pouch containing the stent and delivery system.
   b. Check the temperature exposure indicator on the pouch to confirm that the black dotted pattern with a grey background is clearly visible. See “Warnings” section.
   c. After careful inspection of the pouch looking for damage to the sterile barrier, carefully peel open the pouch and extract the stent delivery system from the tray. Examine the device for any damage. If it is suspected that the sterility or performance of the device has been compromised, the device should not be used.
   d. Flush the flushing valve of the stent delivery system with heparinized saline using a 3-cc syringe to expel air. Continue to flush until heparinized saline weeps from the distal catheter end.
   e. Flush the guidewire lumen of the stent delivery system with heparinized saline using a 20-cc syringe to expel air. Continue to flush until heparinized saline flows out of the wire lumen at the distal catheter tip.
   f. Evaluate the distal end of the catheter to ensure that the stent is contained within the outer sheath. Do not use if the stent is partially deployed.

**Stent Deployment Procedure**

1. **Insertion of Introducer Sheath or Guiding Catheter and Guidewire**
   a. Gain access at the appropriate site utilizing the appropriate accessory equipment compatible with the stent delivery system.
   b. Insert an .035” (0.89 mm) guidewire of an appropriate length through the introducer sheath or guide catheter.

2. **Dilation of Lesion**
   a. If appropriate, pre-dilate the lesion using standard PTA techniques.
   b. Remove the PTA balloon catheter from the patient maintaining lesion access with the guidewire. **Note:** No predilation is generally done with malignant biliary strictures. However, if the physician determines that predilation is necessary, standard PTA techniques may be used. **Caution:** During dilation, never expand the balloon such that dissection complication could occur.

3. **Introduction of Stent Delivery System**
   a. Ensure locking pin is still in place. **Note:** If the locking pin is not in place, system performance may be compromised and another system should be used.
   b. Advance the stent delivery system over the guidewire through the sheath introducer to the lesion site. **Note:** If resistance is met during delivery system introduction, the system should be withdrawn and another system should be used. **Caution:** Always use an appropriate size introducer sheath for the implant procedure to protect vessel and access site.

4. **Slack Removal**
   a. Advance the stent delivery system past the lesion site.
   b. Pull back the stent delivery system until the radiopaque stent markers (leading and trailing ends) move in position so that they are proximal and distal to the lesion site. **Caution:** Slack in the catheter shaft either outside or inside the patient may result in deploying the stent beyond the lesion site.
5. **Stent Deployment**
   a. Verify that the delivery system's radiopaque stent markers (leading and trailing ends) are proximal and distal to the target lesion.
   b. Ensure that the introducer sheath does not move during deployment.
   c. Remove locking pin from handle.
   d. Initiate one-handed stent deployment by rotating the tuning dial with thumb and index fingers in a clockwise direction (direction of arrow) while holding the handle in a fixed position [Figure 2].
   e. While using fluoroscopy, maintain position of the radiopaque stent markers relative to the targeted lesion site. Watch for the distal radiopaque markers to begin separating. Separation of the distal stent markers signals that the stent is unsheathed. Continue turning the tuning dial until the distal end of the stent obtains full apposition with the vessel wall. **Note:** Only the initial 40 mm of the stent may be unsheathed using the tuning dial.
   f. With maintaining a fixed handle position, pull back the deployment lever to unsheathe the remainder of the stent [Figure 3]. **Note:** Failure to maintain a fixed handle position or constraining the catheter shaft during deployment may result in stent compression (shortening) or elongation.
   g. Stent deployment is complete when the proximal markers appose to the vessel wall and the outer sheath radiopaque marker is proximal to the inner shaft stent stop. **Note:** The stent may be deployed using two hands (“Pin and pull” method) by holding the proximal end of the handle stationary with one hand and sliding the deployment lever back towards the stationary hand [Figure 4].

6. **Post-deployment Stent Dilatation**
   a. Advance the deployment lever to its pre-deployment position [Figure 1] while maintaining the handle in a fixed position. Recover the delivery system by pushing the lever as far forward as possible and then by turning the dial counter-clockwise, while keeping pressure on the lever, until the lever reaches the end of the slot and the tip is re-sheathed. While using fluoroscopy, withdraw the entire delivery system as one unit, over the guidewire and out of the sheath introducer. **Caution:** The delivery system is not designed for the use of power injection.
   b. Using fluoroscopy, visualize the stent to verify full deployment.
   c. If incomplete expansion exists within the stent at any point along the lesion, post-deployment balloon dilatation (standard PTA technique) can be performed.
   d. Select an appropriate size PTA balloon catheter and dilate the lesion with conventional technique. The inflation diameter of the PTA balloon used for post dilatation should approximate the diameter of the reference vessel. Remove the PTA balloon from the patient.

7. **Post Stent Placement**
   a. A post stent angiogram should be obtained.
   b. Remove the guidewire and sheath and establish hemostasis. **Note:** Physician experience and discretion will determine the appropriate post-procedure drug regimen for each patient.
   c. Close the entry wound as appropriate.
   d. Discard the delivery system, guidewire, and sheath.
IX. MRI Safety Information

A patient with the S.M.A.R.T. stent may be safely scanned under the following conditions. Failure to follow these conditions may result in injury to the patient.

<table>
<thead>
<tr>
<th>Name/identification of device</th>
<th>Cordis S.M.A.R.T. Stents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nominal values of static magnetic field (T)</td>
<td>1.5 T and 3.0 T</td>
</tr>
<tr>
<td>Maximum spatial field gradient (T/m) and (Gauss/cm)</td>
<td>30 T/m (3000 Gauss/cm)</td>
</tr>
<tr>
<td>RF excitation</td>
<td>Circularly polarized (CP)</td>
</tr>
<tr>
<td>RF transmit coil type</td>
<td>Whole body transmit coil, Head RF transmit-receive coil</td>
</tr>
<tr>
<td>RF receive coil type</td>
<td>Any receive only coil may be used</td>
</tr>
<tr>
<td>Maximum whole body SAR (W/kg)</td>
<td>1.0 W/kg for patient landmarks below the umbilicus, 2.0 W/kg for patient landmarks above the umbilicus</td>
</tr>
<tr>
<td>Limits on scan duration</td>
<td>15 minutes of continuous RF (a sequence or back to back series/scan without breaks) followed by a wait time of 10 minutes if this limit is reached</td>
</tr>
<tr>
<td>MR image artifact</td>
<td>The presence of this implant produced an image artifact of approximately 9 mm when imaged with a spin echo pulse sequence and a 3.0 T MRI system</td>
</tr>
</tbody>
</table>

If information about a specific parameter is not included, there are no conditions associated with that parameter.

X. How supplied

The Cordis S.M.A.R.T.* CONTROL® Nitinol Stent System is supplied sterile (by ethylene oxide gas) and is intended for ONE USE ONLY. Also, included in the packaging: One (1) stent implant card.

DISCLAIMER OF WARRANTY AND LIMITATION OF REMEDY

THERE IS NO EXPRESS OR IMPLIED WARRANTY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ON THE CORDIS PRODUCT(S) DESCRIBED IN THIS PUBLICATION. UNDER NO CIRCUMSTANCES SHALL CORDIS BE LIABLE FOR ANY DIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OTHER THAN AS EXPRESSLY PROVIDED BY SPECIFIC LAW. NO PERSON HAS THE AUTHORITY TO BIND CORDIS TO ANY REPRESENTATION OR WARRANTY EXCEPT AS SPECIFICALLY SET FORTH HEREIN.

Descriptions or specifications in Cordis printed matter, including this publication, are meant solely to generally describe the product at the time of manufacture and do not constitute any express warranties.

Cordis Corporation will not be responsible for any direct, incidental, or consequential damages resulting from reuse of the product.

Protected under one or more of the following U.S. patents: 5,843,244; 6,019,778; 6,129,755; 6,312,454; 6,312,455; 6,342,067; 6,425,898; 6,503,271 and other patents pending in the U.S. and other countries.

Cordis Corporation
14201 North West 60th Avenue
Miami Lakes, Florida 33014, USA

November 2019

© 2019, Cardinal Health. All Rights Reserved. CORDIS, the Cordis LOGO, S.M.A.R.T., CONTROL and CARDINAL HEALTH are trademarks of Cardinal Health and may be registered in the US and/or in other countries.